drug cell human

Trends starting between two to ten weeks ago

Trend strength:, Trend move:23.38%, Trend start: Tuesday, 2015-02-03

Share on StockTwits

Industries: Biotechnology,Medical Instruments & Supplies,Drug Manufacturers - Other

Description: drug cell human ublituximab GPCRs Phenoxodiol drugs pre-clinical discovery proprietary activity Pracinostat orphan receptors intellectual compounds GPCR Novogen pharmaceutical proteins agents repurchase CLL death disorders signaling Cadus Vulcan lead Protein-coupled function GECS postoperative rituximab exclusive

Top Terms: drug cell human ublituximab GPCRs Phenoxodiol drugs

Trend will be:

Continued - 0%No opinion - 100%Reversed - 0%

[MEIP] MEI Pharma, Inc.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of novel therapies for the treatment of cancer. The company?s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. Its clinical development pipeline also includes ME-344, an isoflavone-derived mitochondrial inhibitor drug candidate that is in Phase Ib trial to treat lung and ovarian cancer; and PWT143, an oral inhibitor of phosphatidylinositide 3-kinase, which is in pre-clinical stage for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Limited.

[OMER] Omeros Corporation

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clinical trial for use durin

[PKI] PerkinElmer, Inc.

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, and laboratory services markets worldwide. The company operates through two segments, Human Health and Environmental Health. The Human Health segment develops diagnostics, tools, and applications to help detect diseases earlier, and to accelerates the discovery and development of critical new therapies. This segment provides early detection for genetic disorders from pre-conception to early childhood, as well as offers digital x-ray flat panel detectors and infectious disease testing for the diagnostics market; and a suite of solutions, such as reagents, liquid handling, and detection and imaging technologies that enable researchers to improve the drug discovery process. Its research portfolio includes instrumentation for automation and detection solutions, in vitro and in vivo imaging and analysis hardware and software, and a portfolio of consumable products, including drug discovery and rese

[TGTX] TG Therapeutics, Inc.

TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two therapies targeting hematological malignancies. Its therapies include TG-1101, a chimeric glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency. The company is based in New York, New York.

News

2015-03-03 08:59:01

Why Omeros Corporation OMER Might Be a Diamond in the Rough - Tale of the Tape

2015-03-02 08:58:01

TG Therapeutics, Inc. to Present at the Cowen and Company 35th Annual Health Care Conference

2015-03-02 08:30:00

TG Therapeutics, Inc. to Present at the Cowen and Company 35th Annual Health Care Conference

2015-02-28 22:27:25

Omeros Corporation_s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use

2015-02-26 19:08:03

10-K for PerkinElmer, Inc. United States

2015-02-26 09:00:00

MEI Pharma to Present at Cowen and Company Health Care Conference

2015-02-24 16:05:00

PerkinElmer to Present at Barclays Capital Global Healthcare Conference

2015-02-24 13:49:03

PERKINELMER INC Files SEC form 10-K, Annual Report

2015-02-19 07:00:00

Omeros Corporation_s Phase 2 OMS721 Trial Resulting in Extended Access for Compassionate Use

2015-02-18 11:05:00

PerkinElmer to Present at Cowen and Company 35th Annual Health Care Conference

2015-02-10 09:01:00

4 Biotech Stocks Under $10 Triggering Breakouts: Amarin, Exelixis and More

2015-02-09 04:02:04

PERKINELMER INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits

2015-02-09 03:42:01

Investors_ Radars Failed to Catch Omeros Corporation OMER, Has Yours? - Tale of the Tape

2015-02-09 03:00:00

PerkinElmer Elects Sylvie Grégoire to its Board of Directors

2015-02-06 04:01:44

MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report

2015-02-05 14:48:16

Lightning Round: Why you should buy Box again

2015-02-04 03:30:00

TG Therapeutics, Inc. to Present at the 17th Annual BIO CEO & Investor Conference

2015-02-03 12:01:00

Omeros Closes $84 Million Public Offering of Common Stock and Pre-Funded Warrants

2015-02-03 02:00:12

PerkinElmer Inc. PKI: New Analyst Report from Zacks Equity Research - Zacks Equity Research Report

2015-02-02 11:53:52

OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Statements and Ex

2015-01-30 08:20:06

PerkinElmer Beats Q4 Earnings & Revenues, View Optimistic - Analyst Blog

2015-01-30 08:11:00

Perkinelmer PKI Earnings Report: Q4 2014 Conference Call Transcript

2015-01-29 18:14:13

PerkinElmer profit tops estimates on strong newborn screening

2015-01-29 18:09:52

PerkinElmer tops Street 4Q forecasts

2015-01-29 11:39:41

PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2015-01-29 11:23:45

PerkinElmer profit tops estimates on strong sales of newborn screening tests

2015-01-29 11:05:00

PerkinElmer Announces Financial Results for the Fourth Quarter of 2014

2015-01-29 04:15:00

PerkinElmer Named 2014 “Company of the Year” by Instrument Business Outlook

2015-01-29 03:42:24

Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants

2015-01-29 03:32:00

Omeros Prices $75 Million Public Offering of Common Stock and Pre-Funded Warrants

2015-01-29 02:07:04

Q4 2014 PerkinElmer Inc Earnings Release - After Market Close

2015-01-29 02:00:00

5 Under-$10 Health Care Stocks Setting Up to Trade Higher

2015-01-28 11:01:00

Omeros Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

2015-01-28 09:38:55

HALFTIME FINAL TRADES 1/28/15

2015-01-28 07:58:00

FMHR Final Trade: ABBV, PKI & CSX

2015-01-27 12:45:10

Will PerkinElmer_s PKI Earnings Disappoint This Season? - Analyst Blog

2015-01-26 04:41:02

MEI Pharma MEIP Is in Oversold Territory: What_s Next? - Tale of the Tape

2015-01-23 11:13:00

PerkinElmer Board Declares Quarterly Dividend

2015-01-22 01:00:00

Jim Cramer_s Top Stock Picks: NFLX FOLD TGTX

2015-01-21 12:00:20

TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events

2015-01-20 11:31:30

TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi

2015-01-16 11:56:50

Point72 Asset Management begins a new position in MEI Pharma

2015-01-15 12:45:00

PerkinElmer to Hold Earnings Call on Thursday, January 29, 2015

2015-01-15 04:21:19

TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-15 03:30:00

TG Therapeutics, Inc. to Provide an Update on Its Clinical Programs and Corporate Goals for 2015 at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-08 03:45:50

TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-08 03:30:00

TG Therapeutics, Inc. to Present at the 33rd Annual J.P. Morgan Healthcare Conference

2015-01-07 11:41:33

TG THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit

2014-12-22 11:05:00

PerkinElmer to Present at J.P. Morgan 33rd Annual Healthcare Conference

2014-12-22 11:05:00

NIRI San Diego Elects 2015 Board Members

2014-12-22 04:00:00

MEI Pharma Reaches Response Milestone in Phase II Clinical Trial of Pracinostat in Refractory Myelodysplastic Syndrome

2014-12-17 12:01:22

TG THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit

2014-12-17 11:05:00

MEI Pharma Completes Public Offering of Common Stock

2014-12-17 04:08:30

MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-12-17 03:36:10

TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors

2014-12-17 03:30:00

TG Therapeutics, Inc. Announces Appointment of Kenneth Hoberman to Board of Directors

2014-12-15 11:05:00

PerkinElmer Completes Acquisition of Perten Instruments

2014-12-12 03:00:00

MEI Pharma Announces Pricing Of Public Offering Of Common Stock

2014-12-12 01:17:37

TG Therapeutics, Inc. TGTX in Focus: Stock Soars 21.2%

2014-12-11 05:14:00

Global Mammography Market is Projected to be $2.8 Billion by 2020

2014-12-10 11:17:18

MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock

2014-12-10 11:01:00

MEI Pharma Announces $45 Million Proposed Public Offering of Common Stock

2014-12-09 12:02:16

TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-12-09 06:46:57

Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 Ublituximab in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety

2014-12-09 06:10:00

Preliminary Data From Ongoing Phase I/II Dose Escalation Study of TG-1101 Ublituximab in Combination With TGR-1202 in Heavily Pre-treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity and Safety

2014-12-09 01:03:02

MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-12-08 08:41:34

Data From Phase 2 Clinical Trial of TG-1101 Ublituximab and Ibrutinib Shows Compelling Clinical Activity in Patients With Previously Treated, High-Risk Chronic Lymphocytic Leukemia CLL

2014-12-08 04:02:32

MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-12-08 03:30:00

MEI Pharma Reports Significant Clinical Activity In Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia

2014-12-06 13:55:03

Interim Data From Phase 1 Dose Escalation Clinical Trial of TGR-1202, the Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity and Lack of Hepatic Toxicity in Patients With Relapsed/Refractory Chronic Lymphocytic Leuk

2014-12-04 03:32:09

MEI PHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of Se

2014-12-04 01:00:00

MEI Pharma Announces Election of Pharmaceutical Industry Veteran Kevan Clemens to Board of Directors

2014-12-02 07:08:14

PerkinElmer, UCLA and OncoSec Collaborate to Evaluate Patient-Selection Biomarker in Immunotherapy

2014-12-02 03:30:00

MEI Pharma Completes Enrollment in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia

2014-12-02 01:09:22

OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy

2014-12-01 04:00:00

MEI Pharma To Host Analyst And Investor Event

2014-12-01 03:47:45

TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib ImbruvicaR for Patients With Select B-Cell Malignancies

2014-12-01 03:35:00

8:35 am TG Therapeutics announced the initiation of a multi-center, Phase I trial to evaluate the safety and efficacy of the combination of TGR-1202 and ibrutinib for patients with relapsed and/or refractory chronic lymphocytic leukemia and

2014-12-01 03:30:00

TG Therapeutics Announces Collaboration for a Clinical Trial of TGR-1202 in Combination With Ibrutinib ImbruvicaR for Patients With Select B-Cell Malignancies

2014-11-28 11:06:15

PERKINELMER INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibits

2014-11-26 04:00:00

MEI Pharma To Host Annual Meeting Of Stockholders

2014-11-25 11:30:00

TG Therapeutics, Inc. to Present at the 2014 Deutsche Bank BioFEST Conference

2014-11-25 07:30:03

PerkinElmer Inks $266M Deal to Buy Perten Instruments

2014-11-25 02:44:25

Will TG Therapeutics TGTX Continue to Surge Higher?

2014-11-24 04:41:52

New exit: Valedo divests Perten Instruments to PerkinElmer Inc.

2014-11-24 03:30:00

PerkinElmer Enters into Definitive Agreement to Acquire Perten Instruments

2014-11-19 11:05:00

PerkinElmer to Present at Piper Jaffray Healthcare Conference

2014-11-19 02:37:59

OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients

2014-11-19 02:00:00

OMS721 Inhibits Thrombus Formation in Sera from aHUS Patients

2014-11-16 13:08:56

10-Q for TG Therapeutics, Inc.

2014-11-14 10:30:55

TG THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibit

2014-11-14 10:02:50

TG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2014-11-12 15:09:27

10-Q for Omeros Corp.

2014-11-12 05:00:00

MEI Pharma to Present at Stifel Healthcare Conference

2014-11-12 02:28:50

Omeros OMER Catches Eye: Stock Jumps 8.9%

2014-11-11 01:11:25

TG Therapeutics posts 3Q loss

2014-11-10 14:48:39

Omeros posts 3Q loss

2014-11-10 12:30:23

TG THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exh

2014-11-10 12:30:00

Omeros Corp Earnings Call scheduled for 4:30 pm ET today

2014-11-10 12:26:49

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update

2014-11-10 12:15:00

TG Therapeutics, Inc. Announces Third Quarter 2014 Financial Results and Business Update

2014-11-10 12:12:36

PerkinElmer to Present at Jefferies 2014 Global Healthcare Conference

2014-11-10 12:06:45

OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-11-10 12:05:00

PerkinElmer to Present at Jefferies 2014 Global Healthcare Conference

2014-11-10 12:02:00

Omeros Corporation Reports Third Quarter 2014 Financial Results

2014-11-10 03:07:04

Q3 2014 Omeros Corp Earnings Release - After Market Close

2014-11-07 12:15:10

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update

2014-11-07 12:00:00

TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2014 Financial Results and Business Update

2014-11-06 15:08:37

10-Q for PerkinElmer, Inc. United States

2014-11-06 08:08:00

The ASH 2014 Abstract Stampede Just Happened

2014-11-06 06:31:32

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting

2014-11-06 05:39:42

MEI Pharma Reports Improved Response Rates in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia

2014-11-06 05:30:00

TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 56th American Society of Hematology Annual Meeting

2014-11-06 05:05:00

9:05 am MEI Pharma. reports improved response rates in Phase II study of Pracinostat in front line Acute Myeloid Leukemia; 57% CR/CRi rate in 14 evaluable patients

2014-11-06 05:01:00

MEI Pharma Reports Improved Response Rates in Phase II Study of Pracinostat in Front Line Acute Myeloid Leukemia

2014-11-06 03:07:57

Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke

2014-11-06 03:03:30

MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report

2014-11-06 03:00:00

Omeros Announces Positive Data for MASP-2 Inhibitor in Experimental Model of Stroke

2014-11-04 09:09:47

PERKINELMER INC Files SEC form 10-Q, Quarterly Report

2014-11-04 03:07:25

Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014

2014-11-04 03:00:00

Omeros Corporation to Announce Third Quarter 2014 Financial Results on November 10, 2014

2014-10-31 07:49:00

PerkinElmer PKI Earnings Report: Q3 2014 Conference Call Transcript

2014-10-31 07:30:07

PerkinElmer PKI Posts In-Line Q3 Earnings, Revenue Miss

2014-10-30 13:30:31

PerkinElmer Announces Financial Results for the Third Quarter of 2014

2014-10-30 13:00:00

PerkinElmer Inc Earnings Call scheduled for 5:00 pm ET today

2014-10-30 12:38:19

PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-10-30 12:27:00

4:27 pm PerkinElmer reports EPS in-line, misses on revs; lowers FY14 guidance; approved a new 8 mln share repurchase program

2014-10-30 12:21:49

PerkinElmer meets 3Q profit forecasts

2014-10-30 12:05:00

PerkinElmer Announces Financial Results for the Third Quarter of 2014

2014-10-30 04:26:00

8:26 am Omeros granted pass-through reimbursement status from CMS

2014-10-30 03:52:41

Omidria™ Granted Pass-Through Reimbursement Status from CMS

2014-10-30 03:07:05

Q3 2014 PerkinElmer Inc Earnings Release - After Market Close

2014-10-30 03:00:00

Omidria™ Granted Pass-Through Reimbursement Status from CMS

2014-10-29 12:56:22

PerkinElmer Acquires Ceiba Solutions, Inc.

2014-10-29 04:30:00

MEI Pharma Advances Clinical Study Of Mitochondrial Inhibitor ME-344 In Small Cell Lung And Ovarian Cancers

2014-10-28 12:59:11

Will PerkinElmer PKI Disappoint This Earnings Season?

2014-10-27 09:20:55

Wainwright Sees TG Therapeutics As Take-Out Target

2014-10-27 04:19:45

UPDATE: H.C. Wainwright Initiates Coverage On TG Therapeutics On Significant Long-Term Upside

2014-10-27 03:32:16

Coverage initiated on TG Therapeutics by H.C. Wainwright

2014-10-24 16:35:23

Nasdaq stocks posting largest volume increases

2014-10-24 16:35:19

Nasdaq stocks posting largest percentage increases

2014-10-24 16:35:19

Nasdaq stocks posting largest percentage increases

2014-10-23 16:03:03

Nasdaq stocks posting largest percentage decreases

2014-10-23 12:50:32

PerkinElmer Board Declares Quarterly Dividend

2014-10-23 12:05:00

PerkinElmer Board Declares Quarterly Dividend

2014-10-23 11:10:02

Omeros Falls as Enrollment for OMS824 Study is Suspended

2014-10-22 13:45:43

PerkinElmer Launches Mantra™ Quantitative Pathology Imaging System for Cancer Immunology Research

2014-10-22 02:52:48

Omeros OMER Crumbles: Stock Tanks by 12.3%

2014-10-21 04:23:09

Omeros suspends mid-stage trial of Huntington_s drug, shares fall

2014-10-21 04:06:00

Omeros Provides Update on PDE10 Inhibitor Program

2014-10-21 03:00:00

Omeros Provides Update on PDE10 Inhibitor Program

2014-10-13 23:09:23

MEI Pharma MEIP Soars: Stock Adds 5.5% in Session

2014-10-07 03:00:21

OMEROS CORP Files SEC form 8-K, Entry into a Material Definitive Agreement

2014-10-03 12:05:00

PerkinElmer to Hold Earnings Call on Thursday, October 30, 2014

2014-09-29 12:46:30

OMEROS CORP Files SEC form 8-K, Material Modification to Rights of Security Holders, Financial Statements and Exhibit

2014-09-23 12:52:16

TG THERAPEUTICS, INC. Files SEC form 8-K/A, Entry into a Material Definitive Agreement

2014-09-23 04:01:54

TG THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement

2014-09-23 03:30:00

TG Therapeutics Announces Exercise of License Option for Its Novel, Next Generation PI3K-Delta Inhibitor, TGR-1202

2014-09-18 06:15:39

TG Therapeutics TGTX in Focus: Stock Gains 16.1%

2014-09-18 05:00:00

MEI Pharma To Present At BioCentury_s NewsMakers Conference

2014-09-15 03:14:41

TG THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-09-15 03:00:00

TG Therapeutics Announces Special Protocol Assessment SPA Agreement With the FDA for Its First Phase 3 Clinical Trial of TG-1101 ublituximab in Combination With ImbruvicaR ibrutinib for Patients With Previously Treated Chronic Lymph

2014-09-15 02:57:21

Increased Earnings Estimates Seen for Omeros Corporation OMER: Can It Move Higher?

2014-09-13 09:04:11

MEI PHARMA, INC. Financials

2014-09-12 12:05:44

PERKINELMER INC Files SEC form 8-K, Change in Directors or Principal Officers

2014-09-12 08:20:00

5 Breakout Stocks Under $10 Set to Soar

2014-09-09 05:15:55

MEI PHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-09-09 05:00:00

MEI Pharma Reports Fiscal Year 2014 Results

2014-09-09 04:01:21

MEI PHARMA, INC. Files SEC form 10-K, Annual Report

2014-09-08 12:27:57

UPDATE -- TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

2014-09-08 05:25:00

TG Therapeutics, Inc. to Present at the 16th Annual Rodman & Renshaw Global Investment Conference

2014-09-04 02:41:26

TG Therapeutics TGTX Worth Watching: Stock Up 9.1%

2014-09-02 05:06:58

MEI PHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits

2014-09-02 04:30:00

MEI Pharma Completes Enrollment In Randomized Phase II Clinical Trial Of Pracinostat In Front Line Myelodysplastic Syndrome

2014-09-01 23:00:00

Louis Culot Appointed as BioData_s CEO

2014-08-29 00:16:28

Two Portfolios. Pick One.

2014-08-19 09:04:30

OMEROS CORP Financials

2014-08-18 12:10:03

Ligand Up on Multi-Program Captisol Deal with Avion Pharma

2014-08-15 03:30:00

TG Therapeutics Announces Novel _Chemo-free_ Triple Therapy Combination Clinical Study for Patients With Chronic Lymphocytic Leukemia and Other B-cell Malignancies

2014-08-12 09:04:16

PERKINELMER INC Financials

2014-08-12 03:39:48

Coverage initiated on PerkinElmer by Stifel

2014-08-11 12:10:42

OMEROS CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-08-11 12:03:53

OMEROS CORP Files SEC form 10-Q, Quarterly Report

2014-08-11 12:03:00

Omeros Corporation Reports Second Quarter 2014 Financial Results

2014-08-08 03:12:21

Falling Earnings Estimates Signal Weakness Ahead for TG Therapeutics TGTX

2014-08-08 03:00:00

Omeros to Present at the Wedbush PacGrow 2014 Life Sciences Management Access Conference

2014-08-06 05:00:00

MEI Pharma To Present At Wedbush PacGrow Life Sciences And Canaccord Genuity Growth Conferences

2014-08-05 09:15:54

PERKINELMER INC Files SEC form 10-Q, Quarterly Report

2014-08-01 08:16:00

Dr. Phillip P. Chan, the CEO and President of CytoSorbents Corporation CTSO, Interviews with The Wall Street Transcript

2014-08-01 05:54:54

PerkinElmer Q2 Earnings Meet but Revenues Miss Estimates

2014-07-31 13:21:09

PerkinElmer profit meets Wall Street view; not seeking inversion

2014-07-31 13:00:00

PerkinElmer Inc Earnings Call scheduled for 5:00 pm ET today

2014-07-31 12:34:56

PERKINELMER INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits

2014-07-31 12:26:45

PerkinElmer 2nd quarter profit meets Wall Street view

2014-07-31 12:05:00

PerkinElmer Announces Financial Results for the Second Quarter of 2014

2014-07-31 09:04:13

TG THERAPEUTICS, INC. Financials

2014-07-31 03:07:05

Q2 2014 PerkinElmer Earnings Release - After Market Close

2014-07-24 12:57:00

PerkinElmer Board Declares Quarterly Dividend

2014-07-24 12:37:27

TG THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report

2014-07-22 09:24:15

Why TG Therapeutics, Inc. Stock Was Whipsawed

2014-07-11 05:00:00

3 Biotech Stocks Under $10 to Trade for Breakouts

2014-07-09 03:00:19

Omeros Slumps: OMER Falls 10.4% in Session

2014-07-07 03:48:09

Omeros OMER Enters Overbought Territory

2014-07-02 04:18:00

4 Biotech Stocks Under $10 to Watch for Breakout Trades

2014-06-26 02:37:55

Omeros Corporation OMER Gains: Stock Up 8.92%

2014-06-25 10:47:55

Qualifying Speculation In Omeros Corporation

2014-06-12 05:21:17

Omeros OMER Enters Overbought Territory

2014-06-10 04:30:00

MEI Pharma Reports High Response Rates In Phase II Study Of Pracinostat In Front Line Acute Myeloid Leukemia

2014-06-09 05:00:00

MEI Pharma To Present At Wells Fargo Healthcare Conference

2014-06-06 09:15:57

2 Small-Cap Biotechs for Your Watchlist

2014-06-03 13:40:04

Omeros_ Omidria Gets FDA Nod

2014-06-03 11:05:00

PerkinElmer Launches Newborn Screening Program with China’s National Health and Family Planning Commission

2014-06-02 04:37:11

Moving Average Crossover Alert: MEI Pharma MEIP

2014-05-08 05:00:00

MEI Pharma to Present at Bank of America Merrill Lynch and UBS Healthcare Conferences

2014-05-08 04:31:34

MEI PHARMA, INC. Files SEC form 10-Q, Quarterly Report

2014-05-05 05:00:00

MEI Pharma Initiates Clinical Study Of Mitochondrial Inhibitor Drug Candidate ME-344 In Small Cell Lung And Ovarian Cancers

2014-03-25 12:25:32

PerkinElmer to Showcase Wide Range of Innovative Offerings

2014-03-21 03:08:24

Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference

2014-03-19 14:14:52

Omeros Closes $40.25 Million Public Offering of Common Stock

2014-03-18 05:37:31

MEI Pharma To Present At Cowen Health Care And ROTH Conferences

2014-03-18 05:37:30

MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia

2014-03-14 06:43:03

TG Therapeutics, Inc. Announces $18.1 Million Underwritten Sale of Common Stock to a Single Institutional Investor

2014-03-14 05:46:51

Omeros Prices $35.0 Million Public Offering of Common Stock

2014-03-13 13:45:56

Omeros Announces Proposed Public Offering of Common Stock

2014-03-13 12:30:45

Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

2014-03-10 03:38:33

Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS

2014-03-06 04:15:03

Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial

2014-03-05 12:10:01

TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results and Business Update

2014-03-05 06:50:21

Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds

2014-03-04 05:01:32

Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program

2014-02-28 12:31:39

PerkinElmer Launches Innovative High Throughput Imaging System for Clearer and Faster Visualization of Disease Markers in Tissue

2014-02-28 10:15:00

PerkinElmer Launches Innovative High Throughput Imaging System for Clearer and Faster Visualization of Disease Markers in Tissue

2014-02-26 06:14:55

Omeros to Present at Cowen and Company 34th Annual Health Care Conference

2014-02-19 10:55:50

PerkinElmer to Present at Cowen and Company 34th Annual Healthcare Conference

2014-02-19 03:32:03

Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824

2014-02-11 03:36:05

Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders

2014-02-05 03:25:11

FDA Grants Fast Track Designation to Omeros_ OMS824 Huntington_s Disease Program

2014-02-03 03:38:03

Omeros Announces Positive Data after Completion of Dosing in Phase 1 Clinical Trial with OMS721

2014-01-29 10:45:07

PerkinElmer to Present at Leerink Global Healthcare Conference

2014-01-29 03:11:59

Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial

2014-01-24 10:23:13

PerkinElmer Board Declares Quarterly Dividend

2014-01-23 05:46:32

PerkinElmer Introduces Novel Research Tools to Accelerate Discovery of More Effective Therapies for Life Threatening Diseases at the Society for Laboratory Automation and Screening SLAS 2014 Conference

2014-01-20 10:05:00

PerkinElmer Introduces Novel Research Tools to Accelerate Discovery of More Effective Therapies for Life Threatening Diseases at the Society for Laboratory Automation and Screening SLAS 2014 Conference

2014-01-13 13:21:23

TG Therapeutics, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference

2014-01-08 10:49:16

PerkinElmer to Hold Earnings Call on Thursday, January 30, 2014

2014-01-06 23:55:23

January 7th, 2014 - WaferGen Bio-systems Acquires a Leading Next-Generation Sequencing NGS Library Preparation Business and Announces Changes to its Board of Directors

2014-01-02 10:35:52

PerkinElmer to Present at J.P. Morgan 32nd Annual Healthcare Conference

2013-12-18 03:25:13

FDA Grants Orphan Drug Designation to Omeros_ OMS721 for Complement-Mediated Thrombotic Microangiopathies

2013-12-06 05:02:17

TG Therapeutics, Inc. Launches Combination Clinical Trial of TG-1101 and Ibrutinib in Patients With Select B-Cell Malignancies

2013-12-05 13:10:09

TG Therapeutics, Inc. Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting

2013-11-26 06:31:26

TG Therapeutics, Inc. to Present at the 2013 Deutsche Bank BioFEST Conference

2013-11-25 05:51:37

TG Therapeutics, Inc. Initiates First Combination Clinical Trial of TG-1101 and TGR-1202 in Patients With Relapsed and/or Refractory CLL and NHL

2013-11-21 10:47:48

PerkinElmer Announces Executive Appointment

2013-11-11 13:00:09

TG Therapeutics, Inc. Announces Third Quarter 2013 Financial Results and Business Update

Comments

You have to sign in to write a comment.

No comments yet.